VNDA
Vanda Pharmaceuticals Inc. · Healthcare · Biotechnology
Momentum-inputs (vergelijkbare managers): breedte van houders 0.0% · aandelenstroom +0.5% · netto nieuwe posities -5.9% · formule
Alle eigendomscijfers: uitsluitend gevolgde 13F-managers, posities in gewone aandelen, rapportageperiode Q3 2025
| Kwartaal | Houders | Δ | Aandelen | Gerapporteerde waarde | Nieuw | Uitstappen |
|---|---|---|---|---|---|---|
| Q3 2026 | 2 | 0 | 45.26K | $205,128 | n/a | n/a |
| Q2 2026 | 76 | 0 | 37.76M | $231.07M | +7 | −7 |
| Q1 2026 | 78 | +6 | 33.85M | $233.91M | +14 | −8 |
| Q4 2025 | 72 | -1 | 30.64M | $270.14M | +1 | −2 |
| Q3 2025 | 17 | 0 | 25.97M | $129.59M | n/a | −1 |
| Q2 2025 | 15 | 0 | 24.58M | $116.00M | n/a | n/a |
| Q1 2025 | 12 | 0 | 9.69M | $44.48M | n/a | n/a |
| Q4 2024 | 12 | +1 | 8.66M | $41.48M | +1 | n/a |
| Q3 2024 | 10 | -1 | 7.15M | $33.54M | n/a | −1 |
| Q2 2024 | 11 | n/a | 6.99M | $39.47M | n/a | n/a |
| # | Manager | Aandelen | Δ aandelen | Waarde | Hun gewicht | Gehouden | ||
|---|---|---|---|---|---|---|---|---|
| 1 | BlackRock ✦ (passief) | 8.92M | -5.5% | $44.50M | 0.0% | ▼ Trim | 2 | SEC ↗ ×10 |
| 2 | The Vanguard Group ✦ (passief) | 3.59M | +0.4% | $17.90M | 0.0% | ▲ Add | 2 | SEC ↗ ×4 |
| 3 | Renaissance Technologies ✦ | 3.48M | +0.8% | $17.35M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 4 | Millennium Management ✦ | 3.25M | +4.2% | $16.22M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 5 | Geode Capital Management ✦ (passief) | 1.39M | -17.7% | $6.95M | 0.0% | ▼ Trim | 6 | SEC ↗ ×2 |
| 6 | State Street Global Advisors ✦ (passief) | 1.27M | +0.4% | $6.34M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 7 | AQR Capital Management ✦ | 668.47K | +392.5% | $3.34M | 0.0% | ▲ Add | 6 | SEC ↗ ×4 |
| 8 | Two Sigma Investments ✦ | 662.30K | +25.7% | $3.30M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 9 | Morgan Stanley ✦ | 637.50K | n/a | $3.18M | 0.0% | n/c | 1 | SEC ↗ ×7 |
| 10 | Marshall Wace ✦ | 581.25K | +23.2% | $2.90M | 0.0% | ▲ Add | 4 | SEC ↗ ×3 |
| 11 | JPMorgan Chase ✦ | 399.79K | n/a | $1.99M | 0.0% | n/c | 1 | SEC ↗ ×10 |
| 12 | Goldman Sachs Group ✦ | 339.70K | n/a | $1.70M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 13 | Citadel Advisors ✦ | 263.81K | +78.5% | $1.32M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 14 | Wellington Management ✦ | 189.05K | -35.4% | $943,345 | 0.0% | ▼ Trim | 6 | SEC ↗ ×3 |
| 15 | Fidelity (FMR) ✦ | 179.54K | +11.1% | $895,908 | 0.0% | ▲ Add | 2 | SEC ↗ ×2 |
| 16 | D. E. Shaw & Co. ✦ | 122.33K | -25.5% | $610,412 | 0.0% | ▼ Trim | 6 | SEC ↗ ×2 |
| 17 | T. Rowe Price ✦ | 29.26K | +9.3% | $146,000 | 0.0% | ▲ Add | 6 | SEC ↗ |
"Hun weging" = het aandeel van de positie in de gerapporteerde 13F-aandelenwaarde van die manager: de overtuigingsmaatstaf. ✦ = gecureerde manager.
Nieuwe kopers
| Geen nieuwe bijgehouden kopers dit kwartaal. |
Verlaten
| Norges Bank | $542,800 | was 0.0% |
Volledige marktcontext: over ALLE 13F-indieners (SEC gestructureerde data, Q1 2026): 168 houders, 45.91M aandelen, $293.46M gerapporteerd. Dit betreft een andere, oudere periode dan de bovenstaande cijfers van het gevolgde universum; beide worden nooit gecombineerd.
Wat de gevolgde houders van dit effect het vaakst nog meer bezitten: aantallen gedeeld eigendom, geen fundamentele relaties.